Tada Yasumasa, Ishihara Shunji, Ito Takafumi, Matsui Kosuke, Sonoyama Hiroki, Oka Akihiko, Kusunoki Ryusaku, Fukuba Nobuhiko, Mishima Yoshiyuki, Oshima Naoiki, Moriyama Ichiro, Yuki Takafumi, Kawashima Kousaku, Sato Shuichi, Adachi Kyoichi, Ikeuchi Hiroki, Kinoshita Yoshikazu
Department of Internal Medicine II, Shimane University, Japan.
Intern Med. 2013;52(17):1899-902. doi: 10.2169/internalmedicine.52.0340.
Systemic AA amyloidosis is a complication of various inflammatory diseases including Crohn's disease (CD). Amyloid nephropathy is the most common clinical presentation of AA amyloidosis leading to renal failure, and affected patients often require hemodialysis and ultimately renal transplantation. We herein report the successful use of infliximab as maintenance therapy for amyloid nephropathy in a patient with CD. In the present patient, surgical treatment and infliximab infusion immediately induced a remission of CD, and scheduled infliximab therapy successfully maintained the patient's stable condition for three years, with a significant decrease in the serum creatinine level.
